The U.S. Food and Drug Administration (FDA) has qualified the first artificial intelligence tool for drug development, specifically AIM-NASH, designed to aid pathologists in evaluating metabolic dysfunction-associated steatohepatitis (MASH) during clinical trials.

This cloud-based system analyzes liver biopsy images to score key features like fat buildup (steatosis), liver cell damage (hepatocellular ballooning), inflammation levels, and fibrosis stages, following the NASH Clinical Research Network standards.

MASH represents a serious progression of metabolic-associated fatty liver disease, impacting millions in the U.S. with risks of cirrhosis, liver failure, cancer, transplant needs, or death.

Traditional trial assessments rely on multiple pathologists reviewing biopsies independently, leading to inconsistencies and high resource demands. AIM-NASH addresses this by standardizing scores while keeping pathologists in control, they review full slides and AI outputs before finalizing results.

FDA's qualification stemmed from robust studies showing AIM-NASH-assisted pathologist reads matched expert consensus as closely as unaided individual reviews. Pathologists remain fully accountable, ensuring human oversight in this hybrid approach.

As a qualified drug development tool, it streamlines trials, potentially accelerating therapies for MASH by cutting time and variability in histology evaluations

Learn more: FDA Qualifies First AI Drug Development Tool, Will Be Used in 'MASH' Clinical Trials